🇺🇸 FDA
Patent

US 10323027

2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor

granted A61PA61P25/28

Quick answer

US patent 10323027 (2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor) held by Takeda Pharmaceutical Company Limited expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Jun 18 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61P, A61P25/28